Investigator-Initiated Trial Combining Doxorubicin with Checkpoint Inhibitors Yields Durable Complete Response in Metastatic Cardiac Sarcoma

A novel investigator-initiated clinical trial at the University of Colorado Anschutz Cancer Center (搜索)搜索该词条 has produced what researchers describe as an "unbelievable" outcome for at least one patient with metastatic cardiac sarcoma (搜索)搜索该疾病, demonstrating the potential of combining standard chemotherapy with immunotherapy in a rare and aggressive cancer type.

The trial, led by Breelyn Wilky, MD, deputy associate director of clinical research at the CU Anschutz Cancer Center and associate professor of medical oncology, enrolled 61 patients with metastatic soft-tissue sarcomas who had either not yet been treated or had received only one prior line of chemotherapy. Funded in part by the Cancer League of Colorado (搜索)搜索该词条, the study was designed and executed entirely within the cancer center — what Wilky describes as a "homegrown" trial.

Scientific Rationale

The trial's therapeutic strategy rested on a specific immunological hypothesis. "The standard chemotherapy for metastatic soft tissue sarcomas is a chemotherapy drug called doxorubicin查看药品详情," Wilky explained. "One of the interesting things about chemotherapy, especially doxorubicin, is that while people think of chemo as suppressing the immune system, there's actually data that shows that when you first treat someone with doxorubicin, it acts as a danger signal to the immune system. The cancer cells, when they're treated, unleash these chemicals that look very similar to being infected by a virus."

This danger signal triggers the immune system to attack cancer cells — a process Wilky theorized could be augmented by adding checkpoint inhibitors (搜索)搜索该药品, which remove the "brakes" that prevent immune cells from attacking healthy tissue, a mechanism often hijacked by cancer cells to evade immune destruction.

"Immunotherapy aims to boost the immune response and keep the immune response going and get rid of those shut-off signals," Wilky said. "The idea was, could we get better outcomes combining the chemo with checkpoint inhibitors (搜索)搜索该药品 and take advantage of that immune response early on?"

A Patient's Journey

Among the trial's participants, Peter Wessel, a Denver resident and avid skier and mountain biker, emerged as one of the most remarkable responders. Wessel's diagnostic odyssey began in October 2020 when he experienced chest tightness and pain during a mountain biking excursion at Buffalo Creek Recreation Area. Initially diagnosed with pericarditis with effusion, his condition continued to deteriorate.

"I had pain. I had shortness of breath. I'd wake up in the morning in a pool of sweat," Wessel recounted. A PET scan, urged by a friend who was a radiation oncologist, ultimately revealed a large tumor inside his heart — a cardiac sarcoma (搜索)搜索该疾病.

In November 2020, Wessel underwent open-heart surgery to remove the tumor, a procedure that also required implantation of a pacemaker after the heart's electrical signal-generating region was excised. However, the surgery revealed a more dire situation: the cancer had metastasized to his lungs and adrenal gland, classifying it as stage IV disease.

Wessel's initial oncologist delivered a sobering assessment. "She said, 'None of the drugs that we would normally use are going to work here. It's not something you can surgically attack, and you're not really a candidate for radiation therapy,'" Wessel recalled. "'Your only option is to try to get into a clinical trial of immunotherapy drugs for sarcomas at CU Anschutz.'"

Treatment and Outcome

Wessel began treatment with Wilky in May 2021, receiving eight treatments over six months. The response was rapid and pronounced. "The tumors immediately started to stabilize, or even shrink a little bit," Wessel said. "It seemed to have some effect right from the get-go."

Now nearly five years from the start of treatment, Wessel remains drug-free and cancer-free. "He had a lot of metastatic disease at the time he was enrolled, and now he has no evidence of any cancer remaining," Wilky said. "He's close to five years from starting treatment, and he has no progression of his cancer, which is sort of unbelievable."

Wilky noted that while the trial yielded success for some patients, it was not universally effective. "There were two or three patients in the trial who had long-term benefit, and Peter was one of them," she said. Her research team is now focused on identifying biomarkers or patient characteristics that predict response to the combination, as well as investigating whether altering the sequencing of drug administration affects outcomes.

The Case for High-Volume Sarcoma Centers

Wilky emphasized the critical importance of patients with sarcomas seeking care at specialized, high-volume centers. "It's so important for patients who have sarcomas to get evaluated at a high-volume sarcoma center," she said. "If you were to go online and look up cardiac angiosarcoma outcomes, it looks like a death sentence, but that's not true. There are patients who can be cured of their cancer with either chemotherapy or some of these newer agents."

For Wessel, the trial represented more than a treatment option — it was, in his words, "the Hail Mary." He acknowledged the geographic fortune of having a sarcoma-focused clinical trial available in the Denver metro area. "There aren't that many places in the United States where doctors are focused on doing sarcoma studies," he said. "This wasn't a sacrifice for me — it was really the only option I had."

Reflecting on the experience of seeing a patient benefit from a trial built on her own scientific hypothesis, Wilky said: "One of the most incredible things is to walk into a room with a patient who's on a study like this, where it was based on an idea that you had, and to see that patient actually getting benefit. To pull the scans up and go through them with Peter, that was the coolest thing that I've gotten to do in oncology. That's the whole reason we do clinical research."